Moderna Inc said on Wednesday it is working with US government scientists to study an experimental booster shot that targets a concerning new variant of the coronavirus, and has raised its global COVID-19 vaccine production goal for this year by 100 million doses, Reuters reported.
Noubar Afeyan’s Moderna working with scientists on vaccine against new variant of coronavirus
STEPANAKERT, FEBRUARY 25, ARTSAKHPRESS: The US biotech company has produced raw material for a booster shot aimed at addressing the virus variant first found in South Africa that may be more resistant to existing vaccines, it said. It has shipped the vaccine to the US National Institutes of Health, which helped develop Moderna's current vaccine, for additional study.
Moderna is experimenting with several potential ways to combat new variants of the virus.
They include an additional booster shot that targets the variant now prevalent in South Africa and spreading globally, a combined booster shot that mixes its current COVID-19 vaccine with the experimental shot, and an extra booster shot on top of its current two-dose vaccine, the company said.
It will also experiment with using its experimental shot and the combined shot as primary vaccinations against COVID-19, administering two-dose regimens for people who have not yet received a shot and have not been infected.
To note, American Armenian businessman Noubar Afeyan is the co-founder of Moderna Inc.